Effect of Long Term Vitamin D Supplementation on Biomarkers of Inflammation in Latino and African-American Subjects with Pre-Diabetes and Hypovitaminosis D

Abstract

Background Low vitamin D levels are associated with minority subjects, the metabolic syndrome and inflammation. The effect of vitamin D supplementation on markers of inflammation has not been well studied. Objective To evaluate the effects of high doses of vitamin D supplementation for 1 year on serum biomarkers of inflammation in Latino and African-American subjects with pre-diabetes and hypovitaminosis D. Participants and methods Latino (N =69) and African-American (N = 11) subjects who had both pre-diabetes and hypovitaminosis D with a mean age of 52.0 years, a BMI of 32.7 kg/m2 and 70% of whom were female were randomized to receive weekly doses (mean ± SD) of vitamin D (85,300 IU ± 16,000) or placebo oil for 1 year. Serum levels of interleukin-6, tumor necrosis factor, highly sensitive C-reactive protein), plasminogen activator inhibitor 1, and insulin-like growth factor - 1 were measured at baseline, 6 and 12 months. Results Serum 25-OH vitamin D levels of 22 ng/ml at baseline quickly rose to nearly 70 ng/ml in subjects receiving vitamin D and did not change in the placebo group. Two-way repeated measures ANOVA showed no differences between the 2 groups in any of the five selected parameters. Conclusion High dose vitamin D supplementation for 1 year in minority subjects with pre-diabetes and hypovitaminosis D failed to affect serum biomarkers of inflammation.

Effects of Vitamin D Supplementation on IGF-1 and Calcitriol: A Randomized-Controlled Trial

“…By contrast, a few previous uncontrolled or unblinded studies reported an increase in IGF-1 concentrations after vitamin D supplementation [30,31,32]. Differences in study populations and study design may have accounted for these inconsistencies, but the findings of our study along with previous ones [28,29] strongly argue against a clinically relevant effect of vitamin D supplementation on IGF-1 concentrations. This is further supported by the fact that we found no correlation between IGF-1 concentrations and 25(OH)D at baseline.…”

Effects of vitamin D2 or D3 supplementation on glycaemic control and cardiometabolic risk among people at risk of type 2 diabetes: results of a randomized double‐blind placebo‐controlled trial

“…The null effect in the present study of supplementation on several prespecified secondary outcomes is unsurprising in light of the previous similar null reports for anthropometric markers [8,21] and markers of cardiometabolic risk, including blood pressure [8,10,22,23] C-reactive protein [8][9][10]24,25] and liver enzymes [26], while our null finding for the UKPDS CVD risk engine risk score is novel. Our observation of minor effects on some lipid and Apo values is congruent with the past mixed evidence for effects of vitamin D supplementation on lipids [10,27].…”

Evidence-based nutritional and pharmacological interventions targeting chronic low-grade inflammation in middle-age and older adults: A systematic review and meta-analysis

“…Following full text revision of remaining 289 articles, other 240 studies were excluded. Overall, 49 RCTs (Bahr et al, 2011; Bays et al, 2013; Bitzur et al, 2010; Bo et al, 2016; Breslavsky et al, 2013; Caballero et al, 2004; Chandler et al, 2014; Darghosian et al, 2015; Dawczynski et al, 2013; De Jager et al, 2005; de Jager et al, 2014; Duggan et al, 2015; Ebrahimi et al, 2009; Feher et al, 2014; Gagnon et al, 2014; Goldberg et al, 2014; Hass et al, 2014; Hutchins et al, 2013; Krysiak et al, 2011, 2013; Link et al, 2006; Magyar et al, 2012; Mazloom et al, 2013; Militaru et al, 2013; Mohamadshahi et al, 2014; Murphy et al, 2007; Nodari et al, 2011; Ogino et al, 2010; Paoli et al, 2015; Persson et al, 2006; Pooya et al, 2010; Pot et al, 2009; Pradhan et al, 2009; Rajkumar et al, 2014; Sadiya et al, 2015; Schiano et al, 2008; Shaseb et al, 2016; Sinha-Hikim et al, 2015; Sokol et al, 2012; Stricker et al, 2012; Tome-Carneiro et al, 2012; Tousoulis et al, 2008; Troseid et al, 2009; Valentini et al, 2015; van der Zijl et al, 2011; Witte et al, 2014; Xu et al, 2015; Zhao et al, 2009; Zittermann et al, 2009) were selected for the final analysis (one RCT (Rajkumar et al, 2014) was eligible among both omega −3 and probiotics). Fig.…”

“…Ten of 115 potential studies investigated the relationship between vitamin D supplementation (cholecalciferol or ergocalciferol) and levels of inflammatory biomarkers in 1,314 adults (Breslavsky et al, 2013; Chandler et al, 2014; Duggan et al, 2015; Gagnon et al, 2014; Sadiya et al, 2015; Shaseb et al, 2016; Sinha-Hikim et al, 2015; Sokol et al, 2012; Stricker et al, 2012; Zittermann et al, 2009). Table 7 shows main characteristics of included trials.…”